World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
29250
World Ranking
15487
National Ranking
503

Overview

Tarik Asselah is affiliated with Université Paris Cité in France and has contributed extensively to the field of medicine with a focus on hepatology and infectious diseases. Their research spans several key areas, including hepatitis B and C virus studies, liver disease diagnosis and treatment, and viral epidemiology.

The scientist's most cited recent publications include:

  • COVID-19: Discovery, diagnostics and drug development (2020), Journal of Hepatology
  • Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study (2023), The Lancet. Gastroenterology & Hepatology
  • Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection (2022), New England Journal of Medicine
  • EASL Clinical Practice Guidelines on hepatitis delta virus (2023), Journal of Hepatology
  • Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development (2020), Journal of Hepatology

Asselah frequently collaborates with other researchers in the field. Regular co-authors include:

  • Fabien Zoulim
  • Pietro Lampertico
  • Stanislas Pol
  • Victor de Lédinghen
  • Marc Bourlière

The scientist has a substantial presence in several specialized publication venues, primarily:

  • Journal of Hepatology
  • Liver International
  • New England Journal of Medicine
  • JHEP Reports
  • Journal of Viral Hepatitis

Within the broader domain of medicine, their work is distributed among the following subfields:

  • Epidemiology
  • Hepatology
  • Infectious Diseases
  • Pharmacology
  • Endocrinology, Diabetes and Metabolism

Asselah's primary research topics focus on:

  • Hepatitis C virus research
  • Hepatitis B Virus studies
  • Liver disease diagnosis and treatment
  • Hepatitis viruses studies and epidemiology
  • Liver disease and transplantation
  • Hepatocellular carcinoma treatment and prognosis
  • HIV/AIDS drug development and treatment

Best Publications

  • Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

    Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis

    Rami Moucari;Tarik Asselah;Dominique Cazals–Hatem;Hélène Voitot

  • Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

    Rami Moucari;Rami Moucari;Vincent Mackiewicz;Olivier Lada;Olivier Lada;Marie-Pierre Ripault;Marie-Pierre Ripault

  • Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data

    Gioacchino Leandro;Alessandra Mangia;Jason Hui;Paolo Fabris

  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

    Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony

  • Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

    Graham S Cooke;Isabelle Andrieux-Meyer;Tanya L Applegate;Rifat Atun

  • Steatosis in chronic hepatitis C: why does it really matter?

    T Asselah;L Rubbia-Brandt;P Marcellin;F Negro

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • COVID-19: Discovery, diagnostics and drug development.

    Tarik Asselah;David Durantel;Eric Pasmant;George Lau

  • Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.

    Ana-Carolina Cardoso;Rami Moucari;Claudio Figueiredo-Mendes;Marie-Pierre Ripault

  • Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C

    Sarah Maylin;Sarah Maylin;Michelle Martinot–Peignoux;Michelle Martinot–Peignoux;Rami Moucari;Nathalie Boyer

  • Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues.

    Ivan Bièche;Cèline Narjoz;Tarik Asselah;Sophie Vacher

  • Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

    Christophe Hézode;Tarik Asselah;K Rajender Reddy;Tarek Hassanein

  • CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients.

    Vivien Béziat;Vivien Béziat;Vivien Béziat;Olav Dalgard;Tarik Asselah;Philippe Halfon

  • Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

    W. Ray Kim;Thomas Berg;Tarik Asselah;Robert Flisiak

  • Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

    Ira M. Jacobson;Ira M. Jacobson;Eric Lawitz;Edward J. Gane;Bernard E. Willems

  • Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study

    Jean-Pierre Zarski;Nathalie Sturm;Jérôme Guechot;Adeline Paris

  • Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

    Tarik Asselah;Kris V. Kowdley;Neddie Zadeikis;Stanley Wang

Frequent Co-Authors

Patrick Marcellin
Patrick Marcellin Université Paris Cité
Marc Bourlière
Marc Bourlière Hôpital Saint Joseph
Graham R. Foster
Graham R. Foster Queen Mary University of London
Nathalie Boyer
Nathalie Boyer Université Paris Cité
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Dominique Valla
Dominique Valla Université Paris Cité
Edward Gane
Edward Gane Auckland City Hospital
Jean-Pierre Bronowicki
Jean-Pierre Bronowicki University Hospital of Nancy
Peter Ferenci
Peter Ferenci Medical University of Vienna
Christophe Hézode
Christophe Hézode Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens doors to a wide range of specialties and professional tracks. For prospective clinicians looking to fast-track their education, the shortest pmhnp program options allow students to become psychiatric mental health nurse practitioners in less time, providing flexible pathways for advancement.

Those interested in healthcare management may consider administration degrees. If affordability is a priority, the cheapest mha programs online deliver essential skills without overwhelming tuition fees. Comparing program costs is crucial—explore the masters in healthcare administration cost to identify the best value while ensuring accreditation and quality.

For nurses aspiring to the highest clinical roles, Doctor of Nursing Practice (DNP) degrees are increasingly accessible via distance learning. Choosing from the best online dnp programs enables working professionals to advance their expertise and leadership from anywhere.

Best Scientists Citing Tarik Asselah

Trending Scientists

Recently Published Articles